AEterna Zentaris   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Quebec Canada (1991)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2000
NCT00005995
First Marketed Drug
2017
macimorelin (Macrilen)
First NDA Approval
2017
macimorelin (Macrilen)
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AEterna Zentaris